Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuli Tao

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Translational Lung Cancer Research|December 13, 2024
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancerXiuli Tao, Qian Zhang, Pei Yuan, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|August 16, 2022
Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancerDonghui Hou, Xiaomin Zheng, Wei Song, et al.
Translational Lung Cancer Research|February 11, 2021
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancerShijun Zhao, Donghui Hou, Xiaomin Zheng, et al.
Thoracic Cancer|July 21, 2021
Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancerDonghui Hou, Xiaomin Zheng, Wei Song, et al.
Clinical Nuclear Medicine|June 4, 2025
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up StudyXiuli Tao, Qian Zhang, Ning Li, et al.
NPJ Precision Oncology|December 10, 2020
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodesYun Ling, Ning Li, Lin Li, et al.
NPJ Precision Oncology|January 14, 2022
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockadeShuhang Wang, Pei Yuan, Beibei Mao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 4, 2023
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical TrialJun Zhao, Liang Zhao, Wei Guo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2020
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Ning Li, Shunyu Gao, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Translational Lung Cancer Research|December 13, 2024
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancerXiuli Tao, Qian Zhang, Pei Yuan, et al.
Acta Radiologica (Stockholm, Sweden : 1987)|August 16, 2022
Radiomic-signature changes after early treatment improve the prediction of progression-free survival in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancerDonghui Hou, Xiaomin Zheng, Wei Song, et al.
Translational Lung Cancer Research|February 11, 2021
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancerShijun Zhao, Donghui Hou, Xiaomin Zheng, et al.
Thoracic Cancer|July 21, 2021
Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancerDonghui Hou, Xiaomin Zheng, Wei Song, et al.
Clinical Nuclear Medicine|June 4, 2025
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up StudyXiuli Tao, Qian Zhang, Ning Li, et al.
NPJ Precision Oncology|December 10, 2020
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodesYun Ling, Ning Li, Lin Li, et al.
NPJ Precision Oncology|January 14, 2022
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockadeShuhang Wang, Pei Yuan, Beibei Mao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 4, 2023
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical TrialJun Zhao, Liang Zhao, Wei Guo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2026
Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analysesWei Guo, Liang Zhao, Xiaowei Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2020
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Ning Li, Shunyu Gao, et al.
Pageof 2